Jackson Annette M, Amato-Menker Carly, Bettinotti Maria
Duke University, Department of Surgery, DUMC Box 2645, Durham, NC 27710, USA.
West Virginia University, Microbiology, Immunology, and Cell Biology, Morgantown, WV, USA.
Hum Immunol. 2021 Nov;82(11):850-858. doi: 10.1016/j.humimm.2021.07.006. Epub 2021 Sep 30.
The use of Next Generation Sequencing (NGS) to interrogate cell-free DNA (cfDNA) as a transplant diagnostic provides a crucial step in improving the accuracy of post-transplant monitoring of allograft health. cfDNA interrogation provides a powerful, yet minimally invasive, biomarker for disease and tissue injury. cfDNA can be isolated from a variety of body fluids and analyzed using bioinformatics to unlock its origins. Furthermore, cfDNA characteristics can reveal the mechanisms and conditions under which it was generated and released. In transplantation, donor-derived cfDNA monitoring provides a tool for identifying active allograft injury at the time of transplant, infection, and rejection. Multiple detection and interrogation methods for cfDNA detection are now being evaluated for clinical validity and hold the promise to provide minimally invasive, quantitative, and reproducible measures of allograft injury across organ types.
使用下一代测序（NGS）来检测游离DNA（cfDNA）作为移植诊断方法，是提高移植后对同种异体移植物健康状况监测准确性的关键一步。检测cfDNA提供了一种强大但微创的疾病和组织损伤生物标志物。cfDNA可以从多种体液中分离出来，并使用生物信息学进行分析以确定其来源。此外，cfDNA的特征可以揭示其产生和释放的机制及条件。在移植领域，监测供体来源的cfDNA为识别移植时的同种异体移植物活性损伤、感染和排斥反应提供了一种工具。目前正在评估多种用于检测cfDNA的检测和分析方法的临床有效性，有望为跨器官类型的同种异体移植物损伤提供微创、定量且可重复的测量方法。
